1. Home
  2. FAX vs ARVN Comparison

FAX vs ARVN Comparison

Compare FAX & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo abrdn Asia-Pacific Income Fund Inc.

FAX

abrdn Asia-Pacific Income Fund Inc.

N/A

Current Price

$12.82

Market Cap

594.5M

Sector

Finance

ML Signal

N/A

Logo Arvinas Inc.

ARVN

Arvinas Inc.

N/A

Current Price

$7.69

Market Cap

600.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FAX
ARVN
Founded
1986
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
594.5M
600.2M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
FAX
ARVN
Price
$12.82
$7.69
Analyst Decision
Buy
Analyst Count
0
16
Target Price
N/A
★ $13.93
AVG Volume (30 Days)
232.6K
★ 797.9K
Earning Date
01-01-0001
11-04-2026
Dividend Yield
★ 12.09%
N/A
EPS Growth
N/A
★ 58.84
EPS
N/A
★ 1.70
Revenue
N/A
★ $262,600,000.00
Revenue This Year
N/A
$12.76
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$4.42
Revenue Growth
★ N/A
N/A
52 Week Low
$12.60
$6.97
52 Week High
$16.37
$14.22

Technical Indicators

Market Signals
Indicator
FAX
ARVN
Relative Strength Index (RSI) 29.61 42.54
Support Level N/A N/A
Resistance Level $14.72 $8.52
Average True Range (ATR) 0.26 0.32
MACD -0.04 0.01
Stochastic Oscillator 17.48 33.10

Price Performance

Historical Comparison
FAX
ARVN

About FAX abrdn Asia-Pacific Income Fund Inc.

Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: